Source: European Medicines Agency (EU) Revision Year: 2024 Publisher: Mundipharma GmbH, De-Saint-Exupery-Strasse 10, Frankfurt Am Main, 60549, Germany
REZZAYO 200 mg powder for concentrate for solution for infusion.
| Pharmaceutical Form |
|---|
|
Powder for concentrate for solution for infusion. White to pale yellow cake or powder. |
Each vial contains 200 mg rezafungin (as acetate).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Rezafungin |
Rezafungin selectively inhibits fungal 1,3-β-D-glucan synthase. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall which is not present in mammalian cells. Inhibition of 1,3-β-D-glucan synthesis results in rapid and concentration-dependent fungicidal activity in Candida species (spp.). |
| List of Excipients |
|---|
|
Mannitol |
Glass vial with chlorobutyl rubber stopper and aluminium seal with plastic flip-off cap.
Pack size: 1 vial.
Mundipharma GmbH, De-Saint-Exupery-Strasse 10, Frankfurt Am Main, 60549, Germany
EU/1/23/1775/001
| Drug | Countries | |
|---|---|---|
| REZZAYO | Austria, Estonia, France, Croatia, Ireland, Lithuania, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
